


**Amendments to the Claims**

Please amend Claims 5 and 12. Please cancel Claims 16 and 17. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Previously Presented) A compound represented by the formula:




wherein

R<sup>1</sup> is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons;  
R<sup>2</sup> is an aliphatic chain having 10 to 18 carbons;  
R<sup>3</sup> is a cyclic tertiary amine; and  
R<sup>4</sup> is an *in vivo* hydrolyzable group.

2. (Original) The compound of claim 1 wherein R<sup>3</sup> is pyrrolidino.
3. (Cancelled)
4. (Original) The compound of claim 1 wherein R<sup>1</sup> is 4-hydroxyphenyl.

5. (Currently Amended) The compound of claim 1 wherein R<sup>1</sup> is 3,4-ethylenedioxy-3,4-ethylenedioxypyhenyl.
6. (Cancelled)
7. (Previously Presented) A method for treating a patient having Gaucher's disease, Tay Sachs disease, Fabry's disease. Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of the compound of Claim 1 or pharmaceutically acceptable salts thereof.
- 8-11. (Cancelled)
12. (Currently Amended) A compound selected from the group consisting of the formula:



wherein

R<sup>1</sup> is an aromatic structure, an alicyclic structure, a branched aliphatic structure or a linear aliphatic group having 5 to 15 carbons;

R<sup>2</sup> is an aliphatic chain having 10 to 18 carbons;

R<sup>3</sup> is a cyclic tertiary amine;

R<sup>4</sup> is an *in vivo* hydrolyzable group or a hydrogen; and

R<sup>6</sup> is an *in vivo* hydrolyzable group.


13. (Original) The compound of claim 12 wherein R<sup>3</sup> is pyrrolidino.

14-18. (Cancelled)


19. (Previously Presented) A method for treating a patient having Gaucher's disease, Tay Sachs disease, Fabry's disease, Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of the compound of Claim 12 or pharmaceutically acceptable salts thereof.

20-23. (Cancelled)

24. (Previously Presented) A compound selected from the group consisting of the formulas:




and




wherein

n is an integer from about 1 to about 19;  
R<sub>2</sub> is an aliphatic chain having 10 to 18 carbon atoms; and  
R<sub>3</sub> is a cyclic tertiary amine.

25. (Original) The compound of claim 24 wherein R<sup>3</sup> is pyrrolidino.
26. (Cancelled)
27. (Previously Presented) A method for treating a patient having Gaucher's disease, Tay Sachs disease, Fabry's disease, Sandhoff disease or GM1 gangliosidosis, comprising the step of administering to the patient a therapeutically effective amount of a compound selected from the group consisting of the formulas:



and




or pharmaceutically acceptable salts thereof, wherein

n is an integer from about 1 to about 19;  
R<sub>2</sub> is an aliphatic chain having 10 to 18 carbon atoms; and  
R<sub>3</sub> is a cyclic tertiary amine.

28-35. (Cancelled)

36. (Previously Presented) The compound of Claim 12 wherein hydrolyzable groups represented R<sup>4</sup> and R<sup>6</sup> are independently selected from the group consisting of an acetyl, -CO(CH<sub>2</sub>)CH<sub>3</sub> and



, wherein R<sup>5</sup> is an alkyl group.